EHA Library - The official digital education library of European Hematology Association (EHA)

EVIDENCE FOR INTERCLONAL TUMOR COOPERATIVITY IN MEDIATING IBRUTINIB RESISTANCE BY BTK-C481SER EXPRESSING MYD88 MUTATED LYMPHOMA CELLS
Author(s): ,
Guang Yang
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Jiaji Chen
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Xia Liu
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Manit Munshi
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Lian Xu
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Nicholas Tsakmaklis
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Maria Demos
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Amanda Kofides
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Maria Luisa Guerrera
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Gloria Chan
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Christopher Patterson
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Kirsten Meid
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Joshua Gustine
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Toni Dubeau
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Patricia Severns
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Jorge Castillo
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Zachary Hunter
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Jinhua Wang
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Sara Buhrlage
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
,
Nathanael Gray
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
Steven Treon
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
(Abstract release date: 05/17/18) EHA Library. Yang G. 06/16/18; 214536; S831
Guang Yang
Guang Yang
Contributions
Abstract

Abstract: S831

Type: Oral Presentation

Presentation during EHA23: On Saturday, June 16, 2018 from 12:30 - 12:45

Location: Room A7

Background
Acquired ibrutinib resistance due to BTKCys481 mutations occurs in B-cell malignancies, including those with MYD88 mutations. BTKCys481 mutations are usually sub-clonal, and their relevance to clinical progression remains unclear.

Aims
We sought to define the signaling pathways that promote ibrutinib resistance in MYD88 mutated WM and ABC DLBCL cells. Furthermore, we sought to delineate mechanisms responsible for promoting ibrutinib resistance in neighboring BTK wild-type tumor cells.

Methods
We engineered BTKCys481Ser and BTKWT expressing MYD88 mutated WM and ABC DLBCL cells, and performed signaling studies that included pathways responsible for aberrant MYD88 signaling, and downstream BTK signaling. Furthermore, cytokine release was evaluated by multiplex assay and correlated to findings in patients who progressed on ibrutinib after acquisition of BTK Cys 481 mutations. Lastly, co-culture experiments with BTK Cys 481 mutated and unmutated cells were performed and viability assessed.

Results
Comparing to BTKWT, BTKCys481Ser expressing cells re-activates BTK–PLCγ2–ERK1/2 signaling in the presence of ibrutinib. Use of ERK1/2 inhibitors triggered apoptosis in BTKCys481Ser expressing cells, and showed synergistic cytotoxicity with ibrutinib. ERK1/2 re-activation in ibrutinib treated BTKCys481Ser cells was accompanied by release of many pro-survival and inflammatory cytokines, including IL-6 and IL-10 that were also blocked by ERK1/2 inhibition. To clarify if cytokine release by ibrutinib treated BTKCys481Ser cells could protect non-transduced BTKWT MYD88 mutated malignant cells, we used a TranswellTM co-culture system, and showed that non-transduced BTKWT MYD88 mutated WM or ABC DLBCL cells were rescued from ibrutinib induced cell death when co-cultured with BTKCys481Ser but not their BTKWT expressing counterparts (Figure 1). Use of IL-6 and/or IL-10 blocking antibodies abolished the protective effect conferred on non-transduced BTKWT by co-culture with BTKCys481Ser expressing WM or ABC DLBCL cell counterparts. Rebound of IL-6 and IL-10 serum levels also accompanied disease progression in WM patients with acquired BTKCys481 mutations.

Conclusion

Our findings show that the BTKCys481Ser mutation drives ibrutinib resistance in MYD88 mutated WM and ABC DLBCL cells through re-activation of ERK1/2 activation, and can confer a protective effect on BTKWT cells through a paracrine mechanism. The findings provide evidence for interclonal tumor cooperativity in mediating ibrutinib resistance.

Session topic: 19. Non-Hodgkin lymphoma Biology & Translational Research

Keyword(s): B cell lymphoma, ibrutinib, Resistance

Abstract: S831

Type: Oral Presentation

Presentation during EHA23: On Saturday, June 16, 2018 from 12:30 - 12:45

Location: Room A7

Background
Acquired ibrutinib resistance due to BTKCys481 mutations occurs in B-cell malignancies, including those with MYD88 mutations. BTKCys481 mutations are usually sub-clonal, and their relevance to clinical progression remains unclear.

Aims
We sought to define the signaling pathways that promote ibrutinib resistance in MYD88 mutated WM and ABC DLBCL cells. Furthermore, we sought to delineate mechanisms responsible for promoting ibrutinib resistance in neighboring BTK wild-type tumor cells.

Methods
We engineered BTKCys481Ser and BTKWT expressing MYD88 mutated WM and ABC DLBCL cells, and performed signaling studies that included pathways responsible for aberrant MYD88 signaling, and downstream BTK signaling. Furthermore, cytokine release was evaluated by multiplex assay and correlated to findings in patients who progressed on ibrutinib after acquisition of BTK Cys 481 mutations. Lastly, co-culture experiments with BTK Cys 481 mutated and unmutated cells were performed and viability assessed.

Results
Comparing to BTKWT, BTKCys481Ser expressing cells re-activates BTK–PLCγ2–ERK1/2 signaling in the presence of ibrutinib. Use of ERK1/2 inhibitors triggered apoptosis in BTKCys481Ser expressing cells, and showed synergistic cytotoxicity with ibrutinib. ERK1/2 re-activation in ibrutinib treated BTKCys481Ser cells was accompanied by release of many pro-survival and inflammatory cytokines, including IL-6 and IL-10 that were also blocked by ERK1/2 inhibition. To clarify if cytokine release by ibrutinib treated BTKCys481Ser cells could protect non-transduced BTKWT MYD88 mutated malignant cells, we used a TranswellTM co-culture system, and showed that non-transduced BTKWT MYD88 mutated WM or ABC DLBCL cells were rescued from ibrutinib induced cell death when co-cultured with BTKCys481Ser but not their BTKWT expressing counterparts (Figure 1). Use of IL-6 and/or IL-10 blocking antibodies abolished the protective effect conferred on non-transduced BTKWT by co-culture with BTKCys481Ser expressing WM or ABC DLBCL cell counterparts. Rebound of IL-6 and IL-10 serum levels also accompanied disease progression in WM patients with acquired BTKCys481 mutations.

Conclusion

Our findings show that the BTKCys481Ser mutation drives ibrutinib resistance in MYD88 mutated WM and ABC DLBCL cells through re-activation of ERK1/2 activation, and can confer a protective effect on BTKWT cells through a paracrine mechanism. The findings provide evidence for interclonal tumor cooperativity in mediating ibrutinib resistance.

Session topic: 19. Non-Hodgkin lymphoma Biology & Translational Research

Keyword(s): B cell lymphoma, ibrutinib, Resistance

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies